CA125 antibody [X75]
GTX21107
ApplicationsFlow Cytometry, Western Blot, ELISA
Product group Antibodies
ReactivityHuman
TargetMUC16
Overview
- SupplierGeneTex
- Product NameCA125 antibody [X75]
- Delivery Days Customer9
- Antibody SpecificityEpitope specificity group B (ISOBM classification) similar to M-11.
- Application Supplier Note*Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry, Western Blot, ELISA
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDX75
- ConjugateUnconjugated
- Gene ID94025
- Target nameMUC16
- Target descriptionmucin 16, cell surface associated
- Target synonymsCA125; CA125 ovarian cancer antigen; cancer antigen 125; mucin-16; ovarian cancer-related tumor marker CA125; ovarian carcinoma antigen CA125
- HostMouse
- IsotypeIgG1
- Protein IDQ8WXI7
- Protein NameMucin-16
- Scientific DescriptionThis gene encodes a protein that is a member of the mucin family. Mucins are high molecular weight, O-glycosylated proteins that play an important role in forming a protective mucous barrier, and are found on the apical surfaces of the epithelia. The encoded protein is a membrane-tethered mucin that contains an extracellular domain at its amino terminus, a large tandem repeat domain, and a transmembrane domain with a short cytoplasmic domain. The amino terminus is highly glycosylated, while the repeat region contains 156 amino acid repeats unit that are rich in serines, threonines, and prolines. Interspersed within the repeats are Sea urchin sperm protein Enterokinase and Agrin (SEA) modules, leucine-rich repeats and ankyrin (ANK) repeats. These regions together form the ectodomain, and there is a potential cleavage site found near an SEA module close to the transmembrane domain. This protein is thought to play a role in forming a barrier, protecting epithelial cells from pathogens. Products of this gene have been used as a marker for different cancers, with higher expression levels associated with poorer outcomes. [provided by RefSeq, May 2017]
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Jennings VA et al., 2014 Mar 1, Int J CancerRead more
- Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. Wilson EB et al., 2011, PLoS OneRead more